Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study
Abstract Aim There have been no previous reports on the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders. Methods This one‐week, prospective, single‐arm, clinical trial of fixed dose of suvorexant (20 mg if ages 18–64 or 15 mg if age ≥ 65 years) for insomnia includ...
| Egile Nagusiak: | , , , , , , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
Wiley
2019-09-01
|
| Saila: | Neuropsychopharmacology Reports |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1002/npr2.12069 |